Microba Life Sciences Limited is pleased to announce Professor Trent Munro who will be joining as Senior Vice President of Therapeutics. Professor Munro has over 25 years’ research and development experience, including with multinational biopharmaceutical company Amgen.
What will be Munro’s role at Microba?
Chief Executive Officer Dr Luke Reid said, “As the company enters into clinical trials, Professor Munro brings significant pharmaceutical and US drug development experience to advance our therapeutic programs and establish partnerships with large pharmaceutical companies.”
Prof. Trent Munro began work on April 6 and will be leading the therapeutic strategy to progress its valuable drug development programs and pharma partnering engagements.
What is the industry expertise of Munro?
Prof. Munro was based in California with Amgen for over six years, in the role of Executive Director leading a global team. During this time, he played key roles in the translation of molecules from research, through clinical trials, regulatory approval, and global licensure.
This included a diverse range of programs spanning novel biologics, small molecules, nucleic acid-based, cell-based and gene-based therapies across multiple therapeutic areas.
Munro has held several roles in Australia like Director of the National Biologics Facility (NBF), Program Director of the CEPI funded Rapid Response Vaccine pipeline, Director of the ARC Centre for Biopharmaceutical Innovation (CBI) and Senior Group Leader at the Australian Institute for Bioengineering and Nanotechnology (AIBN) at the University of Queensland.
Prior to starting an active career, Professor Trent Munro completed postdoctoral studies in cell biology and developmental genetics at Harvard Medical School and the University of Cambridge and has a PhD in Protein Biochemistry from the University of Queensland.
